Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $15.63, for a total transaction of $156,300.00. Following the completion of the transaction, the chief financial officer now owns 117,622 shares of the company’s stock, valued at approximately $1,838,431.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Amicus Therapeutics traded up $0.24, reaching $16.14, during midday trading on Friday, Marketbeat.com reports. The company had a trading volume of 23,764 shares, compared to its average volume of 1,909,894. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.21 and a quick ratio of 4.15. Amicus Therapeutics, Inc. has a 1 year low of $10.09 and a 1 year high of $17.62. The stock has a market cap of $3.01 billion, a PE ratio of -5.54 and a beta of 1.38.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $16.78 million. research analysts expect that Amicus Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Amicus Therapeutics by 10.1% in the 1st quarter. BlackRock Inc. now owns 15,090,252 shares of the biopharmaceutical company’s stock worth $226,957,000 after buying an additional 1,378,155 shares in the last quarter. Redmile Group LLC grew its stake in Amicus Therapeutics by 7.1% in the 1st quarter. Redmile Group LLC now owns 10,738,658 shares of the biopharmaceutical company’s stock worth $161,509,000 after buying an additional 712,888 shares in the last quarter. Palo Alto Investors LP grew its stake in Amicus Therapeutics by 2.4% in the 1st quarter. Palo Alto Investors LP now owns 6,147,829 shares of the biopharmaceutical company’s stock worth $92,463,000 after buying an additional 141,807 shares in the last quarter. Franklin Resources Inc. grew its stake in Amicus Therapeutics by 1.3% in the 1st quarter. Franklin Resources Inc. now owns 3,767,389 shares of the biopharmaceutical company’s stock worth $56,661,000 after buying an additional 48,490 shares in the last quarter. Finally, Farallon Capital Management LLC grew its stake in Amicus Therapeutics by 25.2% in the 1st quarter. Farallon Capital Management LLC now owns 3,481,000 shares of the biopharmaceutical company’s stock worth $52,354,000 after buying an additional 700,000 shares in the last quarter.
Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. ValuEngine raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, April 13th. Finally, Cowen reaffirmed a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Tuesday, May 8th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Amicus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $19.06.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.